PT Pyridam Farma TbkISX:PYFA -1.09%68 EBITDA Margin % is 3.83% as of Mar. 2026, which is 41% below its 10-year median of 6.47. GuruFocus rates ISX:PYFA with a GF Score™ of 68/100 and a GF Value™ of Rp212.90 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 952 Drug Manufacturers companies, PT Pyridam Farma Tbk ranks worse than 78.36% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
PT Pyridam Farma Tbk EBITDA Margin % Related Terms
PT Pyridam Farma Tbk EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for PT Pyridam Farma Tbk's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:PYFA vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PT Pyridam Farma Tbk's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Pyridam Farma Tbk EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Pyridam Farma Tbk's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where PT Pyridam Farma Tbk's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Pyridam Farma Tbk (ISX:PYFA) has a EBITDA Margin % of 3.83% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PT Pyridam Farma Tbk and its competitors. This is 41% below median its historical median of 6.47. According to the industry distribution chart, PT Pyridam Farma Tbk ranks #746 out of 952 companies in the Drug Manufacturers industry, placing it in the top 78.4%.
Is PT Pyridam Farma Tbk's EBITDA Margin % too high?
PT Pyridam Farma Tbk's current EBITDA Margin % of 3.83% is 41% below median its 10-year median of 6.47. The Drug Manufacturers industry median EBITDA Margin % is 12.47. PT Pyridam Farma Tbk's value of 3.83% is 69.3% below this industry median. Based on the distribution chart, PT Pyridam Farma Tbk ranks #746 out of 952 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, PT Pyridam Farma Tbk has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Pyridam Farma Tbk's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PT Pyridam Farma Tbk ranks #746 out of 952 companies for EBITDA Margin %. This places PT Pyridam Farma Tbk in the lower half of its industry. The industry median EBITDA Margin % is 12.47. PT Pyridam Farma Tbk's value of 3.83% is 69.3% below this benchmark. While the company's 10-year median is 6.47 vs. the industry median of 12.47, PT Pyridam Farma Tbk has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Pyridam Farma Tbk's current EBITDA Margin % of 3.83% is 69.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PT Pyridam Farma Tbk and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Pyridam Farma Tbk's current EBITDA Margin % is 3.83%, which is 41% below median its own 10-year median of 6.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Pyridam Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Pyridam Farma Tbk (ISX:PYFA) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp212.90, compared to a current price of Rp182.00 — trading 14.5% below its estimated fair value. The current EBITDA Margin % is 3.83%, which is 41% below median its 10-year median of 6.47 and 69.3% below the Drug Manufacturers industry median of 12.47. PT Pyridam Farma Tbk's overall GF Score™ is 68/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For PT Pyridam Farma Tbk (ISX:PYFA), the current EBITDA Margin % is 3.83% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Pyridam Farma Tbk (ISX:PYFA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Pyridam Farma Tbk stock appears to be undervalued.
The current stock price of Rp182.00 is trading 14.5% below its estimated GF Value™ of Rp212.90.
GuruFocus considers PT Pyridam Farma Tbk to be Modestly Undervalued.
Key valuation signals for ISX:PYFA:
EBITDA Margin %: 3.83% (41% below median its 10-year median of 6.47)
GF Value™: Rp212.90 vs. price of Rp182.00 (14.5% below fair value)
Industry Position: 69.3% below the Drug Manufacturers median (#746 of 952)
No single metric tells the full story. See the ISX:PYFA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Pyridam Farma Tbk is engaged in the production and development of pharmaceutical medicines and the trading of medical equipment. It manufactures products namely Antibiotics, Vitamins, Supplements, and Traditional herbal care. It operates through two segments namely Pharmaceutical products, Esthetics, and Toll manufacturing services; and Medical equipment Products segment. The company derives maximum revenue from Pharmaceutical products, Esthetics, and Toll manufacturing services. The company's products include consumer health, Derma, prescription, and biomedilab.
68GF Score
Get the complete analysis for ISX:PYFA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:PYFA has been successfully added to your 
